The ability of DhL to leverage elevated ROS levels in cancer cells, coupled with the potential of DhL for targeted therapy against cancers that overexpress antioxidant molecules such as SLC7A11, positions DhL as a promising candidate for further preclinical development. This evidence concerns the gene SLC7A11 and cancer.